Ad
related to: class 1 c antiarrhythmics treatment centers definition
Search results
Results From The WOW.Com Content Network
Class IV agents affect calcium channels and the AV node. Class V agents work by other or unknown mechanisms. With regard to management of atrial fibrillation, classes I and III are used in rhythm control as medical cardioversion agents, while classes II and IV are used as rate-control agents.
ATC code C01 Cardiac therapy is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Class of medications that are competitive antagonists that block the receptor sites for the endogenous catecholamines epinephrine (adrenaline) and norepinephrine (noradrenaline) on adrenergic beta receptors, of the sympathetic nervous system.
Class Ic antiarrhythmic agents markedly depress the phase 0 depolarization (decreasing V max). They decrease conductivity, but have a minimal effect on the action potential duration. Of the sodium channel blocking antiarrhythmic agents (the class I antiarrhythmic agents), the class Ic agents have the most potent sodium channel blocking effects.
ATC code C Cardiovascular system is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] [4]
Quinidine is a class IA antiarrhythmic agent used to treat heart rhythm disturbances. [1] It is a diastereomer of antimalarial agent quinine, [2] originally derived from the bark of the cinchona tree. The drug causes increased action potential duration, as well as a prolonged QT interval. As of 2019, its IV formulation is no longer being ...
Sodium channel blockers (1 C, 77 P) Pages in category "Antiarrhythmic agents" The following 59 pages are in this category, out of 59 total.
The second Cardiac Arrhythmia Suppression Trial (CAST II) modified the enrollment criteria to include patients at higher risk for serious arrhythmia. [4] This included 1) patients enrolled within 4 to 90 days of a previous MI, 2) a left ventricular ejection fraction lower than 40%, 3) prior to enrollment, suppression of PVCs had occurred with the drugs (vs. placebo) using a double-blinded ...